Witnessing the stock’s movement on the chart, on Thursday, Abeona Therapeutics Inc (NASDAQ: ABEO) set off with pace as it heaved 0.48% to $4.22, before settling in for the price of $4.2 at the close. Taking a more long-term approach, ABEO posted a 52-week range of $3.93-$7.54.
The Healthcare sector firm’s twelve-monthly sales growth has been 47.21% for the last half of the decade. Meanwhile, its Annual Earning per share during the time was 47.21%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 174.84%. This publicly-traded company’s shares outstanding now amounts to $52.40 million, simultaneously with a float of $49.18 million. The organization now has a market capitalization sitting at $228.68 million. At the time of writing, stock’s 50-day Moving Average stood at $5.15, while the 200-day Moving Average is $5.72.
Abeona Therapeutics Inc (ABEO) Ownership Facts and Figures
Nothing is more important than checking the behaviour of major investors towards the stock of the Biotechnology industry. Abeona Therapeutics Inc’s current insider ownership accounts for 9.25%, in contrast to 62.41% institutional ownership. According to the most recent insider trade that took place on Nov 13 ’25, this organization’s Director sold 15,000 shares at the rate of 4.74, making the entire transaction reach 71,168 in total value, affecting insider ownership by 62,252.
Abeona Therapeutics Inc (ABEO) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.1 per share during the current fiscal year.
Abeona Therapeutics Inc’s EPS increase for this current 12-month fiscal period is 174.84% and is forecasted to reach -0.13 in the upcoming year.
Abeona Therapeutics Inc (NASDAQ: ABEO) Trading Performance Indicators
Let’s observe the current performance indicators for Abeona Therapeutics Inc (ABEO). It’s Quick Ratio in the last reported quarter now stands at 9.53. Alongside those numbers, its PE Ratio stands at $3.62, and its Beta score is 1.14. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 571.71.
In the same vein, ABEO’s Diluted EPS (Earnings per Share) trailing twelve months is recorded 1.17, a figure that is expected to reach -0.33 in the next quarter, and analysts are predicting that it will be -0.13 at the market close of one year from today.
Technical Analysis of Abeona Therapeutics Inc (ABEO)
Going through the that latest performance of [Abeona Therapeutics Inc, ABEO]. Its last 5-days volume of 2.04 million indicated improvement to the volume of 1.17 million it revealed a year ago. During the previous 9 days, stock’s Stochastic %D was recorded 17.53% While, its Average True Range was 36.29.
Raw Stochastic average of Abeona Therapeutics Inc (ABEO) in the period of the previous 100 days is set at 6.21%, which indicates a major fall in contrast to 13.75% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 0.31 that was higher than 0.28 volatility it exhibited in the past 100-days period.
